{"id":"cyclophosphamide-vincristine-prednisone-dacarbazine","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Myelosuppression"},{"rate":"20-50%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL476","moleculeType":"Small molecule","molecularWeight":"182.19"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cyclophosphamide and dacarbazine work by adding alkyl groups to DNA, which interferes with DNA replication and causes cell death. Vincristine works by binding to tubulin and preventing microtubule formation, which is necessary for cell division. Prednisone suppresses inflammation by inhibiting the production of inflammatory cytokines.","oneSentence":"Cyclophosphamide is an alkylating agent that interferes with DNA replication, vincristine is a vinca alkaloid that inhibits microtubule formation, prednisone is a corticosteroid that suppresses inflammation, and dacarbazine is an alkylating agent that interferes with DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:34.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin's lymphoma"},{"name":"Non-Hodgkin's lymphoma"},{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT03755804","phase":"PHASE2","title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-12-12","conditions":"Hodgkin Lymphoma","enrollment":232},{"nctId":"NCT03407144","phase":"PHASE2","title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-09","conditions":"Hodgkin Lymphoma","enrollment":340},{"nctId":"NCT01920932","phase":"PHASE2","title":"Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-08-12","conditions":"Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma","enrollment":77},{"nctId":"NCT07209059","phase":"PHASE2","title":"PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma","status":"RECRUITING","sponsor":"National Research Center for Hematology, Russia","startDate":"2025-07-29","conditions":"Hodgkin Lymphoma, Hodgkin Disease, Advanced Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT00049595","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2002-08","conditions":"Lymphoma","enrollment":552},{"nctId":"NCT05008224","phase":"PHASE2","title":"Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-10-07","conditions":"Classical Hodgkin Lymphoma","enrollment":146},{"nctId":"NCT02661503","phase":"PHASE3","title":"HD21 for Advanced Stages","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cologne","startDate":"2016-07","conditions":"Classical Hodgkin Lymphoma","enrollment":1500},{"nctId":"NCT02684708","phase":"PHASE3","title":"Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Giessen","startDate":"2015-10-01","conditions":"Classical Hodgkin Lymphoma","enrollment":2200},{"nctId":"NCT06263530","phase":"","title":"Prognostic Significance of ctDNA in HL","status":"RECRUITING","sponsor":"Interni hematologicka klinika FNKV","startDate":"2022-01-02","conditions":"Prognostic Cancer Model","enrollment":500},{"nctId":"NCT00003389","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-06-17","conditions":"Lymphoma","enrollment":854},{"nctId":"NCT01390584","phase":"PHASE2","title":"Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-05-24","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT00822120","phase":"PHASE2","title":"S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-07","conditions":"Lymphoma, Nonneoplastic Condition","enrollment":371},{"nctId":"NCT01118026","phase":"PHASE2","title":"Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-09","conditions":"Lymphoma","enrollment":101},{"nctId":"NCT00433433","phase":"PHASE3","title":"Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2006-10","conditions":"Lymphoma","enrollment":1952},{"nctId":"NCT01356680","phase":"PHASE3","title":"HD17 for Intermediate Stage Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2012-01-13","conditions":"Hodgkin Lymphoma","enrollment":1100},{"nctId":"NCT00433459","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Christine Mauz-Körholz","startDate":"2007-01","conditions":"Lymphoma","enrollment":2134},{"nctId":"NCT00416832","phase":"PHASE2","title":"Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Christine Mauz-Körholz","startDate":"2002-11","conditions":"Lymphoma","enrollment":648},{"nctId":"NCT02800447","phase":"NA","title":"Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2016-06","conditions":"Advanced Hodgkin's Lymphoma","enrollment":92},{"nctId":"NCT02797717","phase":"NA","title":"Treatment for Classical Hodgkin Lymphoma in Children and Adolescents","status":"RECRUITING","sponsor":"GALIA AVRAHAMI","startDate":"2015-11","conditions":"Classical Hodgkins Lymphoma in Children and Adolescents.","enrollment":2200},{"nctId":"NCT01251107","phase":"PHASE3","title":"Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2000-03","conditions":"Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT00004010","phase":"PHASE2","title":"Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1999-10","conditions":"Lymphoma","enrollment":99},{"nctId":"NCT01468740","phase":"PHASE2","title":"Prospective Study on HIV-related Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Harlachinger Krebshilfe e.V.","startDate":"2004-03","conditions":"HIV-associated Hodgkin Lymphoma","enrollment":130},{"nctId":"NCT00970385","phase":"PHASE3","title":"Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"1995-01","conditions":"Peripheral T Cell Lymphoma","enrollment":95}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":218,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CYC, VCR, PRED, DTIC"],"phase":"phase_3","status":"active","brandName":"cyclophosphamide, vincristine, prednisone, dacarbazine","genericName":"cyclophosphamide, vincristine, prednisone, dacarbazine","companyName":"University of Giessen","companyId":"university-of-giessen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclophosphamide is an alkylating agent that interferes with DNA replication, vincristine is a vinca alkaloid that inhibits microtubule formation, prednisone is a corticosteroid that suppresses inflammation, and dacarbazine is an alkylating agent that interferes with DNA replication. Used for Hodgkin's lymphoma, Non-Hodgkin's lymphoma, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}